ClinicalTrials.gg
CompletedNCT01263262Updated Oct 24, 2013

A Comparison of Infection Rates Between Two Surgical Sites

An observational study in Corneal Toxicity, Ototoxicity and Surgical Site Infection, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-10-24.

Sponsored by Mayo Clinic · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Study summary

Does the use of chlorhexidine scrub prior to cutaneous surgery on the face increase the chances of toxicity to the eyes or ears? In addition, does the us eof chlorhexidine scrub on the face prior to cutaneous surgery decrease the chances of a post-operative wound infection?

Read the detailed description

The intent of this proposed prospective observational cohort study is to determine if there is a difference in the incidence of corneal toxicity and/or ototoxicity in study subjects undergoing Mohs micrographic surgery (MMS) on the face if a povidone-iodine preparation is used pre-operatively as compared to a chlorhexidine-alcohol preparation. It has recently been found that the use of a chlorhexidine-alcohol preparation is superior to the use of a povidone-iodine preparation in preventing post-operative surgical-site infections (SSI) in patients undergoing clean-contaminated surgery. However, the use of chlorhexidine on the face has previously been associated with corneal toxicity and ototoxicity. This study will help to further define previously reported risks of corneal toxicity and ototoxicity associated with the use of a chlorhexidine solution on the face.

02

Conditions studied

  • Corneal Toxicity
  • Ototoxicity
  • Surgical Site Infection

Keywords

  • Surgical site infection
  • Corneal toxicity
  • Ototoxicity
  • Povidone-iodine
  • Chlorhexidine-alcohol
03

In context

Ototoxicity

49 studies on the registry are indexed under Ototoxicity; 15 are open to participants now.

This study's enrollment of 600 is above the median of 111 across 14 observational studies indexed under Ototoxicity.

Browse Ototoxicity studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Consecutive patients 18 years of age or older undergoing Mohs micrographic surgery for a skin neoplasm(s) on the face at the Dermatology Surgery Center at the Mayo Clinic in Rochester, Minnesota, and at the University of Toronto in Toronto, Ontario, Canada, will be included. Exclusion criteria will include: those undergoing MMS for a lesion on the eyelid margin, patients with a history of ongoing eye pain, history of a pre-existing corneal ulcer within 12 months prior to surgery, history of a perforated tympanic membrane, and patients with an active infection at the operative site at the time of surgery. If post-operative follow-up is not completed, the study subject will be excluded from the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing an outpatient cutaneous surgical procedure on the face.

Exclusion criteria

Exclusion Criteria:

  • Those who do not consent to participation
  • Those undergoing cutaneous surgery for a lesion on the eyelid margin
  • Patients with a history of ongoing eye pain
  • History of a pre-existing corneal ulcer within 12 months prior to surgery
  • History of a perforated tympanic membrane
  • Patients with an active infection at the surgical site at the time of surgery.
  • If post-operative follow-up is not completed, the study subject will be excluded from the analysis.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (actual)
06

What researchers measure

Primary outcomes

  1. Ocular and Ear Toxicities

    Comparing ocular and ear toxicities between two institutions with differences in aseptic technique.

    Time frame: 1 year

Secondary outcomes

  1. Infection rates

    compare the infections rates between two institutions with different skin prep practices

    Time frame: 1 year

07

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2010
First posted
Dec 20, 2010
Start
Jan 2011
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Last update
Oct 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01263262
Lead sponsor
Mayo Clinic
Responsible party
Jerry Brewer (Associate Professor of Dermatology, Mayo Clinic) — Principal investigator
First posted
Dec 20, 2010
Start date
Jan 2011
Primary completion
Aug 2013
Completion
Aug 2013
Last update
Oct 24, 2013

Study contacts

Jerry Brewer, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion